Insider Buying: CRISM Therapeutics Corporation (LON:CRTX) Insider Purchases 20,182 Shares of Stock

CRISM Therapeutics Corporation (LON:CRTX) insider Gerald Beaney purchased 20,182 shares of CRISM Therapeutics stock in a transaction that occurred on Monday, April 7th. The shares were purchased at an average cost of GBX 988 ($12.62) per share, with a total value of £199,398.16 ($254,789.37).

CRISM Therapeutics Trading Down 15.8 %

Shares of CRTX opened at GBX 8 ($0.10) on Thursday. The company has a market cap of £871,540.90, a price-to-earnings ratio of -1.38 and a beta of 0.81. The business’s fifty day simple moving average is GBX 7.23 and its two-hundred day simple moving average is GBX 8.73. CRISM Therapeutics Corporation has a 12 month low of GBX 5 ($0.06) and a 12 month high of GBX 30.90 ($0.39).

CRISM Therapeutics Company Profile

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour.